The Next Generation, Falling Skies, and Battlestar Galactica are some of the sci-fi shows that get better with every rewatch.

The annual show for the embedded electronics supply chain showcased many innovations in edge AI and connected, intelligent systems that can perceive and act in real time.

S&P Global announced that four companies will join the S&P 500 index as part of its quarterly rebalance. The additions highlight the rising importance of AI infrastructure within the leading US equity ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

Saudi Arabia can push 7 million barrels a day through the Petroline. Its export terminal can load less than half that. The gap was seemingly always the plan.

China’s program to put astronauts on the lunar surface by 2030 has moved from aspiration to engineering reality, with hardware tests, named spacecraft, and a defined mission architecture now on the ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.

An ESOMAR-certified research organization, FMI provides custom and syndicated market reports and consulting services, supporting both Fortune 1,000 companies and SMEs. Its team of 300+ experienced ...

Audi has quietly ended production of its A8 flagship sedan, closing out a nameplate that defined the brand’s luxury ambitions for more than three decades. The German automaker stopped accepting new A8 ...

Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.

Global commercial drone market to reach 1,755.97 USD Billion by 2035. Analysis of BVLOS, Edge AI, and DaaS models across logistics, energy, and agriculture.

Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company ...